The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It’s this:
nhttps://clinicaltrials.gov/ct2/home
Zum, excellent!
But” Does same product fit for all nations and virus mutations?” I think, the answer is _yes_.
I am annoyed that one important aspect has been overshadowed by the Covid debate:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400931/
”Injury, a leading cause of death across all age groups, remains the number one cause of death in U.S. citizens age 1 – 44 years old. Deaths directly attributable to severe trauma often occur within hours of injury, even before hospitalization. Trauma victims who survive their initial injuries to hospitalization in the intensive care unit (ICU) face the possibility of life-threatening complications such as multiple organ failure (MOF), the leading cause of death in these patients. Acute respiratory distress syndrome (ARDS) is the most frequent manifestation of MOF after trauma occurring in 12-25% of injured patients. While studies differ on the mortality attributable to ARDS in trauma patients, injured patients with ARDS and MOF have mortality rates as high as 50-80%. Moreover, ARDS is independently associated with longer hospital stays, increased costs, and worse long-term health related quality of life in trauma patients.”
These patients -like all patients in the ICU - are only treated with drugs given directly into a vein. That is: Traumakine is the first effective treatment also of ARDS in trauma patients.
Now I had time to read the whole article :
”Faron is participating in a WHO study looking for treatments for the coronavirus. According to Jalkanen, the research results should come in less than half a year. The timing depends on how many patients can be recruited. Research is being conducted in South America and India.
According to Jalkanen, the benefit of Synairgen's announcement may be, that more and more people believe that Interferon beta is suitable for the treatment of coronavirus by preventing both viral replication and lung vascular damage.”
According to Faro's CEO Markku Jalkanen, inhaled medicine could help at a time when the virus is only in the upper part of the respiratory system.
... Instead, the intravenous drug protects the blood vessels of the lungs from the inside of seriously ill patients.
“It prevents fluid from leaking into the lungs, which puts the patient at risk of death,” Jalkanen says.
According to Jalkanen, Traumakine is given to an intensive care patient. Synairgen, on the other hand, would be better suited to those in the early stages of the disease.
“In intensive care, there is so much fluid in the patient’s lungs that the inhaled drug does not advance in the lungs. Our medicine prevents blood vessel leakage, which can lead to the patient's death, ”says Jalkanen.
Traumakine and Clevegen are drug candidates, not yet drugs. FDA has granted Traumakine with Fast Track designation which is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Rebif cannot be used intravenously. Faron has the knowledge to formulate Rebif -> Traumakine, that is administered intravenously.
The European Commission has granted Traumakine an orphan designation= eligibility for market exclusivity for 7 years post approval.
Sorry if this is old knowledge here, but in
Lancet 1. February 2014 there is an article (written among others by Sirpa & Juho Jalkanen) : ”We used ....human recombinant IFN-beta-1a (Rebif; Merck Serono, Geneva. Switzerland) formulated for intravenous use (FP-1201) in the clinical trial.
That trial showed four-time reduction in mortality with FP-1201, also Traumakine.